本文由ConnectiveRx市场发展高级副总裁Chris Dowd撰写，回顾并评估2024年11月的预测，给予A-等级评价。文章分析了预期趋势、市场变化及对病人支持策略的影响。
Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx.
Chris revisits his November 2024 forecasts to assess how they’ve held up through mid-2025, giving them an overall grade of A-. He examines which trends played out as expected, where the landscape shifted more dramatically, and how these developments are reshaping patient access strategies.
To learn more, register for ConnectiveRx’s free webinar on September 24:
Building Resilient Patient Support When Industry Change Never Stops.
Read on for Chris’s insights.
Read more »
